ARTICLE | Product Development
Targeting ovarian
Ovarian cancer at ASCO: New targets driven by antiangiogenics in other cancers
June 21, 2010 7:00 AM UTC
Successes with targeted therapies in solid tumors such as colon, breast and lung cancers have led several companies to explore targeted treatment approaches in ovarian cancer, including antiangiogenics and ligand-targeted chemotherapeutics. Presentations at this year's American Society of Clinical Oncology meeting included an abundance of encouraging data.
Standard of care in ovarian cancer is surgery followed by treatment with a platinum-based chemotherapeutic plus a taxane, but SOC does not work very well. About 70-90% of patients relapse because the diagnosis is often made when patients are in advanced stages of disease. Five-year overall survival is 46%...